Why Prescription Drugs Are So Expensive in the US: Tahir Amin on Patents and Access

Podcast snapshot

The podcast explores why prescription drugs are so costly in the United States, focusing on how patent systems and monopoly protections shape prices, and featuring Tahir Amin, a former intellectual property lawyer turned advocate for access to medicines. It also examines the limits of pharmaceutical cost estimates and proposes policy options to improve access.

• Overlapping patents extend monopolies beyond the original active ingredient
• Litigation and settlements can delay generic competition
• There is skepticism about widely cited drug development cost figures
• Potential reforms include one patent per active ingredient and public manufacturing alternatives

Introduction and context

The podcast opens by framing the problem: prescription drugs in the United States cost roughly three times more than in other wealthy nations, a cross‑partisan issue that persists despite proposals from multiple administrations. Tahir Amin, who has spent years as an intellectual property lawyer and later founded iMac Initiatives for Medicine Access and Knowledge, shares a personal and professional trajectory that informs his critique of the patent system. He argues that the core driver of high prices is not merely the cost of drug development but the way patents are structured and expanded over a drug's life.

Patents and the architecture of monopolies

Amin explains the original intent of the patent system as providing a temporary exclusivity to incentivize invention. In practice, pharmaceutical companies have learned to layer additional protections onto a single active ingredient. They file patents for formulations, new indications, new delivery forms, and even reformulations that restart the exclusivity clock. The result is a web of overlapping patents that can push the actual period of market monopoly well beyond the initial 20 year term. A salient example discussed is Keytruda, Merck's cancer drug, where the company has introduced an injectable form to shift patients onto a new, patent‑protected form and extend control over the market, thereby suppressing competition from generics.

From prosecution to settlement

The conversation then turns to the economics of patent filings and litigation. It may cost branded firms tens of thousands to file a patent but millions to litigate. For competitors, pursuing all challenges to every patent is often not economically viable, so settlements frequently include entry delays that extend market exclusivity and delay generic entry. Amin emphasizes that the narrative around drug development costs — the oft‑cited billions to develop a drug — is opaque and nontransparent, lodged behind corporate secrecy. He suggests reframing the policy question around how to make costs more transparent and policy decisions more evidence based.

Nonprofitable illnesses and market failures

The discussion covers diseases that are not highly profitable because there is little patent protection or because the market size is too small. Amin points to Ebola vaccines and monoclonal antibodies as examples where alignment of incentives did not occur until late in outbreaks. He notes that vaccines and treatments for neglected conditions may not attract investment under a system that rewards patents and profits more than public health impact. This leads to the broader critique that the industry is measured by wealth generation for shareholders rather than the number of lives saved or diseases conquered.

Policy ideas and practical reforms

The host and Amin explore concrete policy options. One proposed reform is a one‑exclusivity rule per active ingredient, accompanied by a broader shift away from relying solely on patent incentives. Amin also argues for building public manufacturing capabilities to counterbalance the private sector, referencing California's CalRx as a step toward public production of essential medicines such as insulin. Such public channels could provide a counterweight to private monopolies and potentially lower prices. The conversation also canvasses broader questions about how exclusivity and profits should be measured, and whether alternative incentive models could better align drug development with public health needs.

Case studies and real‑world implications